Evidence map›Paper›PMID 29789900›Full record

ArticleHeart and vessels2018

Associations of sensitive cardiac troponin-I with left ventricular morphology, function and prognosis in end-stage renal disease patients with preserved ejection fraction.

Kenichiro Otsuka, Koki Nakanishi, Kenei Shimada, Haruo Nakamura, Hitoshi Inanami, Hiroki Nishioka, Kohei Fujimoto, Noriaki Kasayuki, Minoru Yoshiyama

Abstract read
PubMed Publisher
In one paragraph

Article in Heart and vessels, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Observational
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kenichiro OtsukaDepartment of Cardiovascular Medicine, Ishikiri-seiki Hospital, Higashi-osaka, 18-28 Yayoi, Higashi-osaka, 550-0022, Japan. otsuka_k@outlook.com.ORCID http://orcid.org/0000-0003-1359-3143
Koki NakanishiDepartment of Cardiovascular Medicine, Baba Memorial Hospital, Sakai, Japan.
Kenei ShimadaDepartment of Cardiovascular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan.
Haruo NakamuraDepartment of Cardiovascular Medicine, Ishikiri-seiki Hospital, Higashi-osaka, 18-28 Yayoi, Higashi-osaka, 550-0022, Japan.
Hitoshi InanamiDepartment of Cardiovascular Medicine, Ishikiri-seiki Hospital, Higashi-osaka, 18-28 Yayoi, Higashi-osaka, 550-0022, Japan.
Hiroki NishiokaDepartment of Cardiovascular Medicine, Ishikiri-seiki Hospital, Higashi-osaka, 18-28 Yayoi, Higashi-osaka, 550-0022, Japan.
Kohei FujimotoDepartment of Cardiovascular Medicine, Ishikiri-seiki Hospital, Higashi-osaka, 18-28 Yayoi, Higashi-osaka, 550-0022, Japan.
Noriaki KasayukiDepartment of Cardiovascular Medicine, Ishikiri-seiki Hospital, Higashi-osaka, 18-28 Yayoi, Higashi-osaka, 550-0022, Japan.
Minoru YoshiyamaDepartment of Cardiovascular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sensitive cardiac troponin I (cTnI) predicts all-cause and cardiovascular mortality in various clinical settings. However, its clinical significance in hemodialysis (HD) patients with preserved left ventricular ejection fraction (LVEF) has not been fully elucidated. This study investigated the association of cTnI with LV morphology and function, and its long-term outcome in HD patients with preserved LVEF. This prospective study consists of 96 HD patients with preserved LVEF (69 ± 8 years and 63% male) who underwent two-dimensional echocardiographic examination and biomarker tests including cTnI, brain natriuretic peptide, and high-sensitive C-reactive protein. The primary endpoint was all-cause death and secondary endpoint was cardiovascular death. Factors independently associated with cTnI were systolic blood pressure (β = - 0.239, p = 0.011), heart rate (β = 0.216, p = 0.021), LV mass index (β = 0.231, p = 0.020), and E to e' ratio (β = 0.237, p = 0.016). During a mean follow-up of 3.6 years, primary and secondary endpoints were observed in 23 (24%) and 18 (19%) patients, respectively. In the multivariate Cox proportional hazard analysis, the upper cTnI tertile has significantly increased risk of all-cause mortality [hazard ratio (HR), 2.69; 95% confidence interval (CI), 1.139-6.386; p = 0.024] and that of cardiovascular death (HR, 4.56; 95% CI 2.021-16.968; p = 0.006) independent of echocardiographic measures and other serum biomarkers. In HD patients with preserved LVEF, serum cTnI levels were significantly associated with diastolic function and risk of mortality independent of echocardiographic variables and other biomarkers.

Indexed as

Risk AssessmentAgedBiomarkersCause of DeathDiastoleEchocardiography, DopplerFemaleFollow-Up StudiesHeart VentriclesHumansJapanKidney Failure, ChronicMaleMiddle AgedPrognosisProspective StudiesBiomarkersTroponin IDiastolic functionHemodialysisPreserved left ventricular functionPrognosisTroponin

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.